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R806disease. There is a precedent for this
approach, because research in
non-human primates contributed
importantly to the development of
deep-brain stimulation for patients
with neurological and psychiatric
diseases [16]. The cell-type specificity
of optogenetics will allow control over
more selective subsets of neurons
than deep-brain stimulation, thereby
providing the potential of more precise
therapies that can be targeted to those
cells that matter for the disease.
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Proper ContextHow does BRCA1’s evolutionarily conserved E3 ligase activity contribute to
DNA damage responses? Genetically engineered cells containing a BRCA1
RING domain mutation have been used to identify Claspin as a new target of
BRCA1 E3 ligase activity in response to specific forms of DNA damage.Bernadette Aressy1
and Roger A. Greenberg1,2,*
The primary cause of hereditary breast
and ovarian cancer syndrome is
heterozygous germline mutation of
the breast cancer early onset genes
BRCA1 and BRCA2. Both BRCA gene
products are essential for efficient
DNA double strand break (DSB)
repair mediated by homologous
recombination (HR). In addition,
BRCA1 acts to integrate the activities
of several protein partners during the
response to DSBs and contributes to
DNA damage-induced checkpoint
activation in part through promoting
ATR-dependent phosphorylation of
checkpoint kinase 1 (CHK1). Within the
context of heterozygous BRCA
patients, tumors lose the wild-type
allele, motivating synthetic lethal
therapeutic approaches that exploitthe tumor-specific HR deficiency [1–4].
A fundamental understanding
of BRCA-directed DNA repair
mechanisms therefore has clear
implications for the effective design
and implementation of DNA-damaging
chemotherapeutics strategies.
The BRCA1 protein is organized into
two main functional domains. The
amino-terminal region contains a RING
domain that imparts E3 ubiquitin ligase
activity, and the carboxy-terminal part
of the protein contains two BRCT
(BRCA1 C-terminal) repeats that bind
to a phosphorylated serine present
within a consensus SPXF motif in
binding partners [5,6]. Mutations
resulting in highly penetrant breast
and ovarian cancers affect either
of these two domains. Because
many pathogenic mutations in the
amino-terminal BRCA1 RING domain
affect its interaction with thestoichiometric binding partner BARD1,
the contributions of BRCA1 E3 ligase
activity to DNA damage responses and
tumor suppression have until recently
remained enigmatic. The advent of
genetically engineered cells andmouse
models has begun to shed light on this
important topic. Ludwig, Baer and
colleagues have generated a mouse
model in which a single amino acid
substitution (I26A) within the RING
domain renders BRCA1 E3 ligase
inactive by disrupting interaction with
E2 enzymes, while leaving intact its
ability to heterodimerize with BARD1
[7,8]. Surprisingly, BRCA1 I26A cells,
both in culture and in mice, are not
deficient in homology-directed repair
of DSBs and do not display sensitivity
to DNA inter-strand crosslinking (ICL)
agents. Furthermore, BRCA1 I26Amice
are not tumor prone. However,
knock-in of a cancer-causing BRCA1
RING domain allele, BRCA1 C61G, that
disrupts E3 ligase activity and BARD1
interaction does lead to DNA repair
deficiency and cancer susceptibility [9].
Collectively, these findings suggest
that BRCA1 E3 ligase activity is
dispensable for its tumor suppressor
and genome integrity functions, while
interaction with BARD1 is the more
relevant target of pathogenic RING
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Figure 1. Differential DNA damage responses to Camptothecin and Mitomycin C treatment during replication.
(A) Topoisomerase poisons such as camptothecin induce replication-associated DNA double strand breaks and trigger a DNA damage
response, which includes BRCA1-dependent ubiquitination of Claspin and activation of CHK1. (B) Forms of DNA damage involving inter-strand
crosslinks are recognized by several Fanconi Anemia proteins, culminating in the monoubiquitination of the FANCD2/FANCI complex. Endo-
nuclease processing of crosslinks is a prerequisite for subsequent repair of the lesion by homologous recombination. Claspin and BRCA1
also participate in promoting FANCD2 activation and BRCA1 is required for the later steps of homologous recombination after DNA double
strand break formation.
Dispatch
R807domain mutations. It should be noted,
however, that embryonic stem cells
carrying the I26A mutation accumulate
cytogenetic rearrangements at
a higher rate than control cells when
subjected to the ICL agent mitomycin C
(MMC) [7]. Interestingly, pathogenic
BRCA1 RING domain mutations have
been described that, like I26A,
selectively disrupt interaction with E2
enzymes while leaving BARD1
interaction intact [10,11]. Moreover,
BRCA1 I26A mice are smaller and male
mice are infertile [8], implying that the
evolutionarily conserved E3 activity
contributes to at least a subset of
BRCA1 functions.
In this issue of Current Biology,
Sato et al. [12] report experiments in
genetically engineered chicken DT-40
cells that identify Claspin as a new
target of BRCA1 E3 ligase activity.
The authors provide evidence that
BRCA1-mediated ubiquitination of
Claspin is required for responses
to topoisomerase poisons, but not
to MMC. Claspin is a reported
BRCA1-interacting partner and is
required along with several other DNA
damage response mediator proteins,
including BRCA1, to promote
ATR-dependent phosphorylation and
activation of CHK1 [13]. The current
study brings forth evidence that BRCA1
selectively ubiquitinates Claspin in
response to topoisomerase inhibitors,
increasing the stability of the protein
and its association with chromatin.By using a ‘hit and run’ strategy,
the authors engineered the DT40
chicken B cell line with a BRCA1
RING domain valine 26 to alanine
mutation (V26A), recapitulating the
I26A change that had been previously
knocked into the murine BRCA1
locus. Phosphorylation and thereby
activation of CHK1 was selectively
compromised in V26A cells treated
with Camptothecin (CPT) or other
topoisomerase inhibitors, as was
Claspin ubiquitination, Rad51 foci
formation, sister chromatid exchange
and cellular resistance to CPT.
Surprisingly, these responses were
specific to topoisomerase inhibitors
since treatment of V26A cells withMMC
did not result in detectable DNA
damage response impairment.
Topoisomerase inhibitors and
ICL agents both result in replication
fork stalling, an event that requires
subsequent intervention by the
claspin–CHK1 pathway for its
resolution (Figure 1). It is thus
somewhat unexpected that BRCA1
E3 ligase activity would be selectively
required for responses to only one of
these agents. MMC acts as a highly
potent alkylating agent and reacts with
nucleophiles present within DNA
bases, resulting in DNA inter-strand
and intra-strand crosslinks as well as
monoalkylation products. ICL damage
is initially recognized by Fanconi
Anemia proteins and subsequently
processed to DSBs that necessitatehomology-directed recombination
repair by BRCA1 and BRCA2. While
BRCA1 E3 ligase activity is seemingly
dispensable for ICL repair, both
BRCA1 and Claspin are required for
FANCD2 assembly into subnuclear
foci [14,15]. On the other hand,
Camptothecin (CPT) is a selective
inhibitor of the topoisomerase type 1B
enzymes that relax DNA during
replication and transcription. CPT
stabilizes the Top1–DNA intermediates
and prevents DNA religation, thereby
creating DSBs that require HR repair
in S phase. Camptothecin treatment
activates the ATM–CHK2 axis
and is also responsible for CHK1
phosphorylation by ATR to arrest the
cell cycle and promote DNA repair [16].
The specific requirement for BRCA1
E3 ligase activity in response to CPT
but not MMC begs several questions.
How is it that BRCA1 ubiquitinates
Claspin in response to topoisomerase
inhibitors but not DNA crosslinks?
Moreover, why does Claspin require
ubiquitination for its stable association
with chromatin only after DNA damage
arising from topoisomerase inhibition?
Perhaps a closer examination of the
responses to each agent will reveal
differences that could account for the
selective requirement for BRCA1 E3
activity (Figure 1). One possibility
is that BRCA1 is placed within
proximity to Claspin at early stages of
topoisomerase-induced DNA damage,
but not during ICL repair, which
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crosslinks to initiate DSB responses.
This difference and the requirement
for different protein complexes during
the initial recognition of each lesion
could potentially account for the
specific requirement for BRCA1 E3
ligase activity in the context of
topoisomerase inhibitor-induced
DSBs. It is interesting to note that
differential requirements for BRCA1 are
observed in response to poly(ADP)
ribose polymerase inhibitors and ICL
agents in mouse cells [17], thus
invoking different BRCA1-dependent
mechanisms to each response.
While the findings from this study
await further investigation in additional
cell lines and in vivo systems, they have
several potential clinical implications.
For example, BRCA1 mutant tumors
may respond differently to
topisomerase inhibitors in comparison
to ICL agents in a manner that depends
on where the BRCA1 mutation is
located. Additionally, resistance
mechanisms to each agent in tumors
may not be equivalent. Finally, the
studies by Sato et al. [12] emphasize
the power of genetic systems to
uncover additional complexity within
cellular DNA damage responses and
our ever-evolving understanding of
how BRCA1 contributes to this
process.
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Weighs the EvidenceThe brain has to weigh incoming sensory evidence against prior beliefs, the
relative weight given to each depending on the relative uncertainties.
Neuroscience now shows how the human brain accomplishes this.Mathieu d’Acremont
and Peter Bossaerts
Decisions are based on a combination
of prior beliefs and evidence: the
latter should be weighted to a greater
extent if one is more uncertain about
the former, and vice versa. In this
issue of Current Biology, Vilares et al.
[1] report experiments involving
a task where perceptual evidence hadto be evaluated appropriately
against prior beliefs. These
experiments have provided
fascinating new insight into the neural
processing behind sophisticated
human reasoning. They show how the
human brain encodes the signals that
are needed to optimally merge
available evidence with prior beliefs in
order to reach a well-informed
decision.Vilares et al. [1] studied a situation
like the following. Imagine you are
playing a guessing game with your
friends Bill and Betty. Bill will throw
a gold coin in the middle of a murky
pond. Betty sees where it landed, but
you do not. You are to guess where the
gold coin is. Betty will help you by
tossing three silver coins in the
direction of Bill’s coin. She will show
you where her coins landed (Figure 1).
To be good at this guessing game,
you primarily need to track how good
Bill and Betty are at coin tossing. If Bill
isn’t good and his coin could land
anywhere despite his aiming for the
middle, while Betty is likely to match
Bill’s toss, then you should relymore on
the evidence Betty shows. Conversely,
if Betty is lousy at coin tossing, while
